BERKSHIRE HATHAWAY INC (BUFFETT WARREN E) sold $69.0M of DVA (indirect holdings)

BERKSHIRE HATHAWAY INC sold 382,563 indirectly-held shares of DAVITA INC. (DVA) at $180.43 ($69.03M total) on 2026-10-27. Filed jointly with BUFFETT WARREN E (10% owner).

Original reporting
SEC EDGAR · BERKSHIRE HATHAWAY INC, BUFFETT WARREN E
Published Oct 29, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 9:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DVA
Neutral
medium confidence
Mentioned
$DVA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DVANeutralLow
01

Why it matters

Traders may treat large-holder sales as a sentiment overhang, but without accompanying company-specific news (earnings, guidance, litigation, or strategy change) the impact is typically modest.

02

Market read

A large 10% owner sale in DaVita is disclosed, which can influence near-term sentiment but does not, by itself, change operating fundamentals.

03

What to watch

No 10b5-1 plan is cited, but the filing still lacks context on whether the sale was pre-planned or driven by tax/liquidity needs.

Relevance 6/10Novelty 5/10Timing: filed 2026-10-29, transaction dated 2026-10-27

Background

The article is an SEC Form 4 insider transaction disclosure, where Berkshire Hathaway is listed as a 10% owner and the sale is reported as indirect holdings.

Company-level read

Ticker impact

$DVANeutralMedium confidence
Context

DaVita disclosed a Form 4 showing Berkshire Hathaway sold 382,563 shares at $180.4305 on 2026-10-27 via an indirect 10% owner position.

Expected impact

Likely mild downward pressure or increased caution as traders weigh incremental supply, though 10b5-1 is not indicated and the filing alone is usually not decisive.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but it does not include a rationale, guidance change, or operational event for DaVita.

Market effects

Limited sector read-through; this is a single large-holder sale rather than a healthcare sector catalyst.

No clear regional spillover beyond US large-cap healthcare sentiment.

Minimal global relevance; the disclosure is US SEC Form 4 specific.

Counterpoint

The sale may be portfolio rebalancing or liquidity management, so it may not signal reduced confidence in DaVita’s fundamentals.

Key entities

  • DAVITA INC.

    Subject of the Form 4 disclosure, where Berkshire Hathaway reported an open-market sale of shares.

  • BERKSHIRE HATHAWAY INC

    Reporter of the Form 4 transaction, selling 382,563 shares at $180.4305 on 2026-10-27.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DVAMed

Washington state accuses largest dialysis providers DaVita, Fresenius of suppressing competition

Washington state sued DaVita and Fresenius Medical Care, alleging they suppress competition by requiring nephrologists to sign noncompete agreements, reducing patient treatment options. The state seeks to void these agreements and impose fines. DaVita denies wrongdoing; Fresenius did not comment. The FTC is also investigating. DaVita operates 51 centers in Washington, Fresenius 29, with some areas having only one provider.

$DVAMedAI 8/10

DaVita (DVA) Q3 2026 Earnings Call Transcript

DaVita (DVA) reported Q3 2026 adjusted operating income of $561M and EPS of $3.82. The company highlighted clinical advancements in fluid management and expanded HD dialyzers, expecting a national rollout by November. DaVita raised its Integrated Kidney Care (IKC) guidance to $65M for 2026, citing improved savings rates and partnerships. Full-year 2026 adjusted operating income is projected to be $2.175B-$2.25B, with EPS between $14.30-$15.20.

$DVAHighAI 9/10

What DaVita (DVA) Said on Its Q3 Earnings Call

DaVita (DVA) reported Q3 earnings, highlighting a 20% year-over-year increase in technology spending and a national rollout of expanded hemodialysis dialyzers. The company expects technology investment growth to decelerate but not decline in 2027. DaVita raised its outlook for Integrated Kidney Care, projecting at least $65 million in adjusted operating income for 2026.

$DVAHighAI 8/10

DaVita Inc (DVA) (Q3 2026) Earnings Call Highlights: IKC Guidance Raised, Expanded HD

DaVita Inc (DVA) narrowed its 2026 adjusted operating income and EPS guidance due to higher US dialysis costs. Revenue per treatment grew 1.1% YoY, while patient care costs rose 2.4%. The new ESRD rule's 3.5% rate increase is expected to have a net impact of 1.5% to 2% for 2027. CEO Javier Rodriguez highlighted growth plans for the IKC business and the company's stance on the HHS Kidney Care National Plan.

$DVAHighAI 9/10

DaVita’s (NYSE:DVA) Q3 2026: beats on revenue but stock drops

DaVita (DVA) reported Q3 2026 revenue of $3.58B, beating estimates by 1.7% YoY. Adjusted EPS of $3.82 exceeded expectations by 6.9%. Management raised full-year EPS guidance to $14.75. Operating margin remained steady at 14%, but free cash flow margin declined to 7.7% from 19.7% YoY. Sales volumes increased 1.2% YoY, reversing a prior decline.